This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 3 of 5 for:    PsiOxus

Mechanism of Action Trial of ColoAd1 (MOA)

This study has been completed.
Information provided by (Responsible Party):
PsiOxus Therapeutics Ltd Identifier:
First received: January 30, 2014
Last updated: September 8, 2016
Last verified: September 2016
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following ColoAd1 administration by intravenous infusion.

Condition Intervention Phase
Resectable Colon Cancer Resectable Non-small Cell Lung Cancer Resectable Bladder Cancer Resectable Renal Cell Carcinoma Biological: Colo-Ad1 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour

Resource links provided by NLM:

Further study details as provided by PsiOxus Therapeutics Ltd:

Primary Outcome Measures:
  • Composite measure of viral delivery and spread [ Time Frame: Up to Day 25 ]
    To assess the pattern of viral delivery and viral spread of ColoAd1 within tumour tissue when administered either by intra-tumoural injection or by intravenous infusion. Viral delivery and spread will be measured by immunohistochemical staining for ColoAd1 in tumour sections taken from patients. Presence of virus will also be detected by qPCR analysis of tumour tissue.

Enrollment: 17
Study Start Date: June 2013
Study Completion Date: April 2016
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intra-tumoural cohort Biological: Colo-Ad1
Oncolytic virus
Experimental: Intra-venous cohort Biological: Colo-Ad1
Oncolytic virus


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

Patients must meet all the following criteria to be eligible for participation:

  • Able and willing to provide written informed consent and to comply with the study protocol
  • Age ≥ 18 years
  • Patients with histologically confirmed resectable colon cancer, NSCLC (squamous and non-squamous), bladder cancer (urothelial cell carcinoma) or RCC (renal cell carcinoma), scheduled for resection of primary tumour and with planned resection of draining lymph nodes for colon cancer
  • Diagnostic colonoscopy performed at the study centre (Cohorts A and B only) or a referral centre (Cohort B only) and a report from this colonoscopy available for the study
  • Tumour size of 3 cm or more in diameter as estimated during diagnostic colonoscopy for cohorts A and B or by CT-scan for cohorts C, D and E.
  • At least 2 weeks since the last dose of any intravenous systemic chemotherapy at time of first administration of ColoAd1
  • Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies.
  • Able to undergo surgery with general anaesthesia
  • Surgery planned and administration of ColoAd1 feasible within

    • 15 days of planned surgery (following IT administration or following first dose of IV administration) for cohorts A and B
    • 10 - 25 days of first ColoAd1 administration for cohorts C, D and E
  • ECOG Performance Status Score of 0 or 1
  • Adequate renal function

    • Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula ≥ 60 mL/min, or measured creatinine clearance ≥60 mL/min,
    • Absence of clinically significant haematuria on urinalysis: dipstick < 2+
    • Absence of clinically significant proteinuria on urinalysis: dipstick < 2+.
  • Adequate hepatic function

    • serum bilirubin <1.5 x ULN
    • AST and ALT ≤ 3 x ULN
  • Adequate bone marrow function:

    • ANC ≥ 1.5 x 109/L,
    • platelets ≥ 100 x 109/L,
    • haemoglobin ≥ 90 g/L
  • Adequate coagulation tests: INR ≤ 1.5 x ULN;
  • For females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative pregnancy test must be documented prior to enrolment;
  • For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of < 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during the treatment period and for at least 3 months after the last dose of study drug;
  • For men: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug

Exclusion Criteria for all patients:

Patients who meet any of the following criteria are not eligible for enrolment:

  • Rectal tumours; (cohorts A and B);
  • An obstructive tumour of the intestine (cohorts A and B only) or of the urinary tract (cohort D);
  • Any condition necessitating surgery in less than 8 days (cohorts A or B) or 10 days (cohorts C, D or E);
  • Pregnant or lactating (nursing) women;
  • Known and/or a history or evidence of significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids at doses higher than dexamethasone 10 mg or equivalent, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks);
  • Splenectomy
  • Prior allogeneic or autologous bone marrow or organ transplantation
  • Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection
  • Active viral disease, positive serology for HIV, hepatitis B or hepatitis C
  • Use of the following anti-viral agents:

    • ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1;
    • or PEG-IFN (within 14 days prior to day 1);
  • Administration of an investigational drug within 28 days prior to first dose of ColoAd1
  • Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1
  • Another primary malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ)
  • Known CNS metastasis
  • Inflammatory diseases of the bowel (cohorts A and B only) or any inflammatory disease that may require treatment with corticosteroids.
  • Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug
  • Known allergy to treatment medication or its excipients
  • Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02053220

Hospital Universitario Madrid Sanchinarro CIOCC
Madrid, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Sponsors and Collaborators
PsiOxus Therapeutics Ltd
  More Information

Responsible Party: PsiOxus Therapeutics Ltd Identifier: NCT02053220     History of Changes
Other Study ID Numbers: ColoAd1-1002
Study First Received: January 30, 2014
Last Updated: September 8, 2016

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Urinary Bladder Neoplasms
Carcinoma, Renal Cell
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Urologic Neoplasms
Urogenital Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Kidney Diseases processed this record on July 19, 2017